RNA sequence adaptation

Patent metadata

Field	Value
Publication number	US-11692002-B2
Application number	US-201816762081-A
Country	US
Kind code	B2
Filing date	Nov 8, 2018
Priority date	Nov 8, 2017
Publication date	Jul 4, 2023
Grant date	Jul 4, 2023

Abstract

The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine. Moreover, the present invention concerns a method for providing an adapted RNA sequence or an adapted RNA mixture.

First claim

The invention claimed is:

1. A method for analysis or purification of a mixture comprising at least two harmonized RNA species, the method comprising:
a) obtaining the coding sequences for at least two RNA species, said at least two RNA species each having a length of 800 to 20,000 nucleotides wherein the sequence of at least one RNA species is adapted by altering the number of A and/or U nucleotides in the RNA sequence with respect to the number of A and/or U nucleotides in the original RNA sequence, said coding sequences of the at least two RNA species having a harmonized number of encoded A and U nucleotides that is no more than 50 different from each other;
b) synthesizing the at least two RNA species to produce at least two harmonized RNA species; and
c) analysing and/or purifying a mixture of said at least two harmonized RNA species by chromatography.

2. The method according to claim 1 , wherein step b) comprises the separate synthesis of the at least two harmonized RNA species.

3. The method according to claim 2 , wherein step b) comprises mixing the at least two harmonized RNA species.

4. The method according to claim 1 , wherein step b) comprises the synthesis of the at least two harmonized RNA species in one batch.

5. The method according to claim 1 , wherein step b) comprises an in vitro transcription step.

6. The method according to claim 1 , wherein at least one RNA species comprises at least 500 nucleotides.

7. The method according to claim 6 , wherein the at least two RNA species are mRNAs.

8. The method according to claim 7 , wherein the at least two RNA species each comprise a 5′-cap structure.

9. The method according to claim 8 , wherein the at least two RNA species each comprise, in 5′ to 3′ direction, the following elements:
a) a 5′-cap structure
b) optionally, a 5′-UTR element,
c) at least one coding region;
d) a 3′-UTR element, and
e) a poly(A) sequence comprising 10 to 200.

10. The method according to claim 8 , wherein the at least two RNA species each encode different Influenza virus hemagglutinin (HA) antigens.

11. The method according to claim 8 , wherein the at least two RNA species each comprise a coding region, wherein the coding region has an increased G/C content compared to the G/C content of an original coding sequence, wherein the encoded amino acid sequence is not modified compared to the amino acid sequence encoded by the corresponding original mRNA.

12. The method according to claim 8 , wherein the method is applied to at least three RNA species.

13. The method according to claim 12 , wherein the at least three RNA species encode different influenza HA antigens.

14. The method according to claim 1 , comprising:
c) analysing the mixture of said at least two harmonized RNA species by chromatography.

15. The method according to claim 1 , wherein the chromatography comprises HPLC.

16. The method according to claim 15 , wherein the chromatography comprises reversed phase HPLC.

17. The method according to claim 16 , wherein the reversed phase HPLC is with a column that comprises a porous material, selected from the group consisting of polystyrene, a non-alkylated polystyrene, an alkylated polystyrene, a polystyrenedivinylbenzene, a non-alkylated polystyrenedivinylbenzene, an alkylated polystyrenedivinylbenzene, a silica gel, a silica gel modified with non-polar residues, a silica gel modified with alkyl containing residues, selected from butyl-, octyl and/or octadecyl containing residues, a silica gel modified with phenylic residues, and a polymethacrylate.

18. The method according to claim 8 , wherein the at least two RNA species each encode different Influenza virus neuraminidase (NA) antigens.

19. The method according to claim 1 , wherein the numbers of A and U nucleotides in the sequences of the at least two harmonized RNA species differ from each other by not more than 20.

20. The method according to claim 19 , wherein the numbers of A and U nucleotides in the sequences of the at least two harmonized RNA species differ from each other by not more than 10.

21. The method according to claim 13 , wherein the numbers of A and U nucleotides in the sequences of the at least two harmonized RNA species differ from each other by not more than 20.

22. The method according to claim 8 , wherein the method is applied to at least four RNA species, wherein the at least four RNA species encode different influenza HA antigens.

Assignees

• CureVac SE

Inventors

• Heinz Stefan
• Roos Tilmann
• Vahrenhorst Dominik
• Conzelmann Markus

Classifications

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• C07H1/06 Primary

  Separation; Purification · CPC title

• C12N15/101 Primary

  by chromatography, e.g. electrophoresis, ion-exchange, reverse phase · CPC title

• A61K39/145

  Orthomyxoviridae, e.g. influenza virus · CPC title

• C12P19/34

  Polynucleotides, e.g. nucleic acids, oligoribonucleotides · CPC title